Pharsight

Teflaro generic

Teflaro is an antibiotic drug owned by Allergan. It contains the active ingredient ceftaroline fosamil and was first authorized for market use on October 29, 2010.

When will Teflaro generic be available?

The generic version of Teflaro could be released after February 10, 2031, when the last patent (US8247400) expires. This patent, titled 'Cephem compounds useful for the treatment of bacterial infections', protects the active compound used in Teflaro.

Teflaro uses

Teflaro is used for treating a variety of bacterial infections. Its active ingredient, ceftaroline fosamil, works by inhibiting bacterial cell wall synthesis, thereby stopping the growth of bacteria.

Teflaro patent expiration

Teflaro holds a total of 3 drug patents, of which 1 has already expired. The remaining patents protect the drug from generic competition until at least February 2031. For more about when Teflaro generic could be available, see the patent expiry plot below. Below are the details of the patent:

Teflaro dosage

Want to ask something?